Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 07, 2025, titled "Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received a Notice of Compliance (NoC) from Health Canada for its ZDS-Varenicline tablets (0.5 mg and 1 mg), used as an aid in smoking cessation. This is the company's first regulatory approval in Canada. The product will be manufactured at Zydus's SEZ facility in Ahmedabad. The Canadian market for Varenicline tablets was approximately 15 million Canadian dollars annually as of December 2024 (per IQVIA data), giving Zydus a new revenue stream in a hard-currency market.
This marks Zydus's entry into the Canadian pharmaceutical market, opening access to a small but meaningful new geography. While the immediate revenue contribution (CAD 15 mn market) is modest relative to Zydus's overall scale, it strengthens the company's international regulatory footprint and export pipeline.